KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested Capital

AbCellera Biologics (ABCL) Equity Ratio (2020 - 2025)

AbCellera Biologics (ABCL) has disclosed Equity Ratio for 6 consecutive years, with 0.71 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Equity Ratio fell 8.15% year-over-year to 0.71, compared with a TTM value of 0.71 through Sep 2025, down 8.15%, and an annual FY2024 reading of 0.78, changed 0.24% over the prior year.
  • Equity Ratio was 0.71 for Q3 2025 at AbCellera Biologics, down from 0.72 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.85 in Q1 2021 and bottomed at 0.71 in Q3 2025.
  • Average Equity Ratio over 5 years is 0.78, with a median of 0.78 recorded in 2023.
  • The sharpest move saw Equity Ratio fell 10.59% in 2022, then rose 6.39% in 2023.
  • Year by year, Equity Ratio stood at 0.78 in 2021, then rose by 2.89% to 0.8 in 2022, then fell by 3.25% to 0.77 in 2023, then increased by 0.24% to 0.78 in 2024, then decreased by 8.41% to 0.71 in 2025.
  • Business Quant data shows Equity Ratio for ABCL at 0.71 in Q3 2025, 0.72 in Q2 2025, and 0.76 in Q1 2025.